View Older Stories View More Recent Stories

Aug 18, 2023 04:34PM Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease
Aug 1, 2023 07:00AM Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
Jul 11, 2023 04:07PM Neurocrine Biosciences (NBIX) Appoints Christine A. Poon to its Board
Jul 11, 2023 04:05PM Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors
Jul 11, 2023 04:01PM Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results
Jun 15, 2023 08:30AM Neurocrine Biosciences' (NBIX) Diurnal Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone
Jun 15, 2023 08:30AM Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023
Jun 8, 2023 04:01PM Neurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
Jun 2, 2023 08:30AM Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate
May 19, 2023 08:30AM Neurocrine Biosciences (NBIX) Announces Publication of Full KINECT-HD Phase 3 Study Results
May 19, 2023 08:30AM Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology
May 15, 2023 08:31AM Neurocrine Biosciences (NBIX) Presents INGREZZA Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
May 15, 2023 08:30AM Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Diso
May 12, 2023 08:30AM Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023
May 2, 2023 04:01PM Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference
May 1, 2023 08:30AM Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week
Apr 12, 2023 04:01PM Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results
Mar 21, 2023 04:01PM Neurocrine Biosciences to Present at the Stifel 2023 CNS Days
Mar 9, 2023 04:30PM Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on P
Mar 9, 2023 08:34AM Neurocrine Biosciences (NBIX) Presents Data on In Vitro Dissolution Performance of INGREZZA Capsule Contents via Soft Foods or Feeding Tube
Mar 9, 2023 08:30AM Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference
Mar 3, 2023 08:31AM Neurocrine Biosciences (NBIX) Presents Data on Improvements Over Time with Long-Term Use of INGREZZA Capsules in Older and Elderly Patients
Mar 3, 2023 08:30AM Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatr
Jan 9, 2023 07:44AM Neurocrine Bio (NBIX), Voyager (VYGR) Enter Pact for Development of Voyager's GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases
Jan 9, 2023 07:00AM Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurologic
Jan 3, 2023 04:01PM Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 22, 2022 04:01PM Neurocrine Biosciences (NBIX) Announces FDA Acceptance of sNDA for Valbenazine
Dec 22, 2022 04:01PM Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
Dec 6, 2022 04:30PM Neurocrine Biosciences (NBIX) Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep Misses Primary Endpoint
Dec 6, 2022 04:01PM Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep
Dec 2, 2022 08:30AM Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022
Nov 3, 2022 09:00AM Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting
Nov 3, 2022 08:30AM Neurocrine Biosciences (NBIX) Presents Additional Phase 3 Data for KINECT-HD Study
Nov 3, 2022 08:30AM Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022
Oct 27, 2022 08:30AM Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
Oct 24, 2022 08:30AM Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022
Oct 19, 2022 08:33AM Neurocrine Biosciences (NBIX) Presents Data on Benztropine
Oct 19, 2022 08:30AM Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference
Sep 29, 2022 11:00AM Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer
Sep 19, 2022 08:31AM Neurocrine Biosciences (NBIX) Presents INGREZZA Data
Sep 19, 2022 08:30AM Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022
Sep 15, 2022 08:46AM Neurocrine Biosciences (NBIX) to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians
Sep 15, 2022 08:45AM Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress
Sep 15, 2022 08:30AM Neurocrine Biosciences (NBIX) Presents New Post-Hoc Analysis of ONGENTYS Capsules Effect on COMT Activity
Sep 15, 2022 08:30AM Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress
Sep 12, 2022 08:30AM Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care
Sep 6, 2022 04:01PM Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Aug 4, 2022 07:05PM Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences
Jul 14, 2022 04:01PM Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
Jun 13, 2022 08:00AM Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022
View More Recent Stories View Older Stories